ストックスクリーナーアプリを入手
49.64
7.94%
3.65
アフターアワーズ：
49.42
-0.22
-0.44%
前日終値:
$45.99
開ける：
$46.43
24時間の取引高:
6.19M
Relative Volume:
0.95
時価総額：
$19.70B
収益：
$2.23B
当期純損益:
$-3.19B
株価収益率:
-6.0936
EPS:
-8.1462
ネットキャッシュフロー:
$-1.60B
1週間 パフォーマンス:
-3.78%
1か月 パフォーマンス:
-6.13%
6か月 パフォーマンス:
+67.53%
1年 パフォーマンス:
+78.88%
1日の値動き範囲:
$46.30
$49.94
1週間の範囲:
$45.40
$51.53
52週間の値動き範囲:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Compare MRNA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
49.64 | 18.25B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
445.04 | 110.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.48 | 63.08B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
898.94 | 53.62B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
289.39 | 38.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 30.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Equal Weight |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-12 | 開始されました | Jefferies | Hold |
| 2025-03-13 | 開始されました | Citigroup | Neutral |
| 2025-02-18 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-01-29 | ダウングレード | Goldman | Buy → Neutral |
| 2024-12-18 | ダウングレード | Argus | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-19 | 開始されました | Berenberg | Hold |
| 2024-11-18 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-09-13 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-09-13 | ダウングレード | Jefferies | Buy → Hold |
| 2024-09-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-08-28 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-08-07 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-08-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-01-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 開始されました | Canaccord Genuity | Hold |
| 2023-11-03 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-11-02 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-08-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-06-26 | アップグレード | UBS | Neutral → Buy |
| 2023-04-26 | 開始されました | Guggenheim | Neutral |
| 2023-03-13 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-02-24 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | アップグレード | Jefferies | Hold → Buy |
| 2022-12-14 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2022-01-26 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-01-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 開始されました | UBS | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Sell |
| 2021-10-15 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-08-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 繰り返されました | Jefferies | Hold |
| 2021-02-01 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-12-16 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | ダウングレード | Needham | Buy → Hold |
| 2020-11-23 | 開始されました | Wells Fargo | Equal Weight |
| 2020-11-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-07-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Argus | Buy |
| 2020-06-08 | 開始されました | Barclays | Overweight |
| 2020-04-30 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-05 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-25 | 開始されました | ROTH Capital | Buy |
| 2019-04-05 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Moderna Inc (MRNA) 最新ニュース
Moderna Gains Almost 8% With Nasdaq Recovery; Cancer Vaccine Pipeline Still a Key Focus - TechStock²
Moderna Says New COVID Vax Doesn't Infringe BioNTech IP - Law360
WINTON GROUP Ltd Invests $800,000 in Moderna, Inc. $MRNA - MarketBeat
Nicollet Investment Management Inc. Acquires Shares of 30,413 Moderna, Inc. $MRNA - MarketBeat
Moderna's Case for Vaccinating Children: Strong Data, Stronger Questions - trialsitenews.com
Moderna, Inc. $MRNA Shares Sold by Letko Brosseau & Associates Inc. - MarketBeat
Moderna Inc stock (US60770K1079): Legal chief share sale and vaccine pipeline keep volatility high - AD HOC NEWS
Moderna Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Moderna’s mRNA-4194 cleared for clinic for Lynch syndrome - BioWorld News
Moderna Inc. stock (US60770K1034): Bank of America lifts price target after strong run - AD HOC NEWS
Does Moderna Need to Start Making Money? - The Globe and Mail
Does Moderna Need to Start Making Money? - The Motley Fool
Capital World Investors Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome - Investing News Network
AIPLA, NAM Rally Behind Moderna's Fight Over Vax Patents - Law360
Moderna’s Lynch syndrome cancer vaccine trial gets UK approval - Investing.com UK
Moderna’s Lynch syndrome cancer vaccine trial gets UK approval By Investing.com - Investing.com South Africa
Inherited cancer risk for 1 in 300: Moderna mRNA trial targets Lynch syndrome - Stock Titan
Moderna CLO Klinger sells $173,550 in shares By Investing.com - Investing.com India
Moderna CLO Klinger sells $173,550 in shares - Investing.com
Moderna (MRNA) legal chief sells 3,471 shares, exercises options and RSUs - Stock Titan
Moderna (MRNA) CFO details RSU vesting and tax share withholding in Form 4 - Stock Titan
MRNA Maintained by B of A Securities -- Price Target Raised to $34 - GuruFocus
Moderna (NASDAQ:MRNA) Price Target Raised to $34.00 - MarketBeat
Moderna, Inc. (MRNA) Stock Analysis: Evaluating The Potential Amidst Volatility - DirectorsTalk Interviews
Havemeyer Place LP Takes Position in Moderna, Inc. $MRNA - MarketBeat
CIBC Asset Management Inc Increases Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Aufman Associates Inc Has $1.27 Million Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
How Investors May Respond To Moderna (MRNA) mRNA Advances in Personalized Cancer and Emerging Infectious Diseases - Yahoo Finance
Norges Bank Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
MRNA Stock Quote Price and Forecast - CNN
Moderna | History, Innovation, Challenges, & Facts | Britannica Money - Britannica
Why Is Moderna (MRNA) Stock Rocketing Higher Today - Yahoo Finance
Moderna gets good news as it searches for life after Covid - Yahoo Finance Singapore
[144] Moderna, Inc. SEC Filing - Stock Titan
Moderna Inc (MRNA) Stock Price, Trades & News - GuruFocus
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
Moderna Stock: Is MRNA Outperforming the Health Care Sector? - Yahoo Finance
Moderna Inc. stock (US60770K1034): EMA committee backs new RSV vaccine as shares bounce on Nasdaq - AD HOC NEWS
Moderna (MRNA) Climbs 7.5% Ahead of Next Week’s Key Updates - Insider Monkey
Moderna rallies on renewed optimism around its Merck-partnered melanoma vaccine program - Quiver Quantitative
Moderna (MRNA) CFO exercises 2,475 RSUs, 1,197 shares withheld for taxes - Stock Titan
Moderna (MRNA) CLO converts RSUs into stock while 1,047 shares withheld for taxes - Stock Titan
Moderna (MRNA) president exercises RSUs, reports tax share withholding - Stock Titan
Moderna (NASDAQ:MRNA) Trading 8.1% HigherShould You Buy? - MarketBeat
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion - Investing News Network
HEALTH ROUNDS-Radiation-emitting implant improves outcomes after brain cancer surgery - marketscreener.com
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026 - Yahoo Finance
Moderna Launches Moderna Direct with “eCommerce Powered by FFF Enterprises™” - Yahoo Finance
Moderna CEPI Ebola Vaccine Work Highlights Broader Infectious Disease Ambitions - Yahoo Finance
Moderna to Present at Upcoming Conference in June 2026 - Investing News Network
Moderna Inc (MRNA) 財務データ
収益
当期純利益
現金流量
EPS
4.65%
1.27%
大文字化:
|
ボリューム (24 時間):